# US 8,569,461 B2 · Humanized anti-interleukin 3 receptor alpha chain antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,461 B2
- Document ID: US8569461B2
- Status: Granted
- Kind: B2
- Application number: 13/256,926
- Filed: 2011-08-17
- Published: 2013-05-30
- Granted: 2013-10-29
- Earliest claimed: 2010-08-17
- Assignees: CSL Limited
- Applicants: Con Panousis
- Inventors: Con Panousis
- Web page: https://patentgrep.com/patent/US8569461B2

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07K 16/244: {Interleukins [IL]}
- C07K 16/465: {with additional modified FR-residues}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides antibodies that bind to interleukin-3 receptor alpha chain and uses thereof.

## Claims

### Claim 1

An isolated or recombinant antibody, which is capable of specifically binding to interleukin (IL)-3Rα chain, wherein the antibody comprises:
(i) a light chain variable region (VL) comprising CDRs 1, 2 and 3 as set forth in SEQ ID NOs: 2, 3 and 4, respectively;
(ii) a heavy chain variable region (VH) comprising CDRs 1, 2 and 3 as set forth in SEQ ID NOs: 5, 6 and 7, respectively; and
(iii) a heavy chain constant region comprising amino acid substitutions S239D and 1332E according to the EU numbering system of Kabat.

### Claim 2 (depends on 1)

The isolated or recombinant antibody of claim 1, which is a humanized antibody, the antibody comprising:
(i) a light chain variable region (VL) comprising an amino acid sequence according to SEQ ID NO: 8 and a heavy chain variable region (VH) comprising an amino acid sequence according to SEQ ID NO: 9; and
(ii) a heavy chain constant region comprising amino acid substitutions S239D and 1332E according to the EU numbering system of Kabat.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the heavy chain constant region constant region comprises a sequence set forth between residues 121-450 (inclusive) of SEQ ID NO: 11.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the antibody is a humanized antibody comprising a light chain comprising a sequence set forth in SEQ ID NO: 13 and a heavy chain comprising a sequence set forth in SEQ ID NO: 11.